Cardiovascular market: A snapshot - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Cardiovascular market: A snapshot

Aug 4, 2001

How often have you heard a person complaining about diabetes? Quite often, right? With increasing level of urbanization, stress index levels have moved in tandem. Diabetes, heart diseases and other life style problems are on the rise. No wonder cardiovascular market is the largest and fastest growing therapeutic segment in the global pharmaceutical market. The global cardiovascular market is estimated to be US$ 46 bn, which is around 10% of the world pharma market and is clocking double-digit growth rates. A patient once afflicted with cardiac problem usually carries the problem through his lifetime and brand switching is lowest in this segment. Cardiovascular segments thus attract larger pie of R&D budget of pharma companies worldwide and new drugs are continually rolled out on a regular basis.

India has the fastest growing diabetes patients, thanks to rapid expansion of urbanization. Statistics rolled out by World Health Organisation predicts in about two decades the number of diabetes patients would leap frog to about 57 m from the current 27 m patients.

The domestic market for cardiovascular segment is estimated to be Rs 9.3 bn, which means a market share of around 7%. The cardiovascular market in India has grown at compounded average rate of 28% in last one decade and has outsmarted all other therapeutic markets.

Cardiovascular Market: Segment wise break-up
Sub-Segment Market Size
(Rs m)
Rate (%)
Beta Blockers 1,318 23.5
ACE Inhibitors 1,259 13.9
Calcium Channel Blockers 2,026 14.4
Hypotensives 945 32.9
Diuretics 335 36.6
Others 823 14.6

Anti-anginals and Hypotensives are broad sub-segments within the cardiovascular category. Anti-anginals are drugs used to remove blockage in arteries ultimately controlling chest pain. Anti-hypertensives are used to control high blood pressures. Diuretics are used to reduce excess level of sodium salt in the body. Usually, patients are required to use multiple drug/medicines for cardiac therapy and thus pharma companies use various combinations of molecules.

The leading players in cardiovascular therapy are mostly domestic companies like Sun Pharma, Torrent, Cadila and ICI Pharma. Share of MNCs is relatively low and their portfolio consists of relatively older molecules.

Apart from the fact that the segment is provides fast growth rates, the margins in the segment are higher due to very limited DPCO exposure. All this is attracting companies to concentrate on this therapeutic segment. Moreover, considering the lifestyle nature of problems, affordability issue is not a major concern in this segment.

Exports of cardiovascular formulations till date have been relatively marginal in the cardiovascular segment. The silver lining is that generic export market for cardiovascular products might open up for Indian companies in a big way in coming years, as some of the prominent molecules in the segment go off patent. However, to sustain export growth in the long-term companies will have race up their research capabilities.

Considering the lucrative market, the segment has higher chances of MNC’s aggressively launching blockbuster products in India post 2005 (when patent protection would be a reality). So brand positioning and basic research will be the key to success and survival for domestic companies. Domestic companies will have to undertake basic research by choice and compulsion to compete against their international counterparts. Otherwise they better have their ‘pulse’ checked at an earlier date.

Equitymaster requests your view! Post a comment on "Cardiovascular market: A snapshot ". Click here!


More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

6 Penny Stocks that Rallied 1,000%+ in One Year (Views On News)

Dec 6, 2021

These penny stocks shed their penny status by surging 1,000% or more in the last one year.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 8, 2021 12:23 PM